TCBP Announces Execution of Non-Binding Letter of Intent for Acquisition of NK Platform Technologies

EDINBURGH, Scotland, April 4, 2024 /PRNewswire/ — TC BioPharm (Holdings) PLC (“TC BioPharm” or the “Company”) (NASDAQ: TCBP) a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced the execution of a non-binding letter of intent as part of its M&A strategy aimed at expanding its therapeutic platform and leveraging […]

April 4, 2024